Sermorelin for Sale USA: Domestic Stock and the 503A Route

Searching sermorelin for sale USA rather than just sermorelin for sale is a deliberate filter, and it is usually driven by four worries: a parcel seized at the border, a long transit in a warm month, a refund that cannot be enforced across jurisdictions, and a seller who cannot be identified if anything goes wrong. All four are reasonable, and three of them are solved by domestic stock.

The fourth is not solved by geography alone, and this is where most domestic-supply pages stop early. A US address makes a seller reachable. It does not make a certificate wider, and it does not put a professional between you and the vial. Those are different problems with different answers.

We link a domestic supplier and earn a commission on purchases through it, which our affiliate disclosure page sets out. It is also why this page spends its second half on the US regulatory picture rather than on the shipping map.

An imported parcel adds a border, and a border adds a decision that nobody involved in your purchase controls. It also adds days, sometimes weeks, and it adds handovers. Domestic stock removes all of that in one move, which is the strongest practical argument for the filter.

Heat exposure is the variable buyers worry about most and can measure least. What ships is a lyophilised powder in a sealed vial, and dry material tolerates ambient transit considerably better than a solution would, which is why parcels move without temperature control. The honest caveat is that no domestic parcel is temperature-logged either. Shorter is better because it is shorter, not because anyone measured it.

The step that recovers some control is at the other end. When the vial arrives, read the lot number stamped on it and match it against the certificate the seller published. On the listing we link, that number is 38-01260229, analysed by MZ Biolabs in Tucson, Arizona on 7 February 2026. Our page on the order end to end works through the arrival check in sequence.

Recourse is the part of the domestic argument that actually holds up. A seller operating in your own jurisdiction has a written policy you can hold them to and a payment relationship your card issuer understands. A seller you cannot identify, in a country you cannot reach, has neither, whatever the policy page says.

It is worth being precise about how far that goes. In the research market the parties who answer are the vendor, under its own published terms, and your bank. There is no adverse event reporting route, no pharmacist and no licensing board holding a file on your purchase, because the material is not supplied as a medicine. That list is short by design rather than by oversight.

The prices, at least, are not in dispute. The listing we link publishes $99.99 as a list price, $72.00 as the site price, and $36.00 with the code, which is $3.60 per milligram on the 10 mg label and $3.18 on the 11.31 mg that lot assayed. Quantity tiers of three, five and ten per cent come off the list separately, and free shipping starts at $250.

This is where sermorelin stops resembling the rest of the peptide market. It was an approved US drug. EMD Serono held two applications for Geref: NDA 019863 for the diagnostic product at 0.05 mg per ampoule, with submissions from May 1991, and NDA 020443 for the therapeutic version at 0.5 mg and 1 mg per vial, approved on 26 September 1997.

Both are recorded as discontinued on Drugs@FDA, and the product record carries the Federal Register determination that the product was not discontinued or withdrawn for safety or effectiveness reasons. There is no current US label, and DailyMed returns no structured product labels for it. That is a commercial history, not a regulatory sanction, and the difference matters for what follows.

Section 503A permits a compounding pharmacy to use a bulk drug substance that is a component of an FDA-approved drug product, even where no USP monograph exists for it. Sermorelin acetate was exactly that. FDA's Category 2 bulk substances list, which flags substances presenting significant safety risks in compounding, names ibutamoren mesylate under both 503A and 503B, along with ipamorelin acetate, GHRP-2, GHRP-6 and kisspeptin-10, while BPC-157, Melanotan II, Selank, Semax, MOTS-c and epitalon were nominated and then withdrawn. Sermorelin appears in none of those places.

A domestic seller labelling material for laboratory use is describing the terms on which it is supplied. It means the seller is not offering it as a medicine, is not making human-use claims, and is not accepting the obligations that come with supplying one. That is a real distinction and it is the reason the price is what it is.

What it does not mean is that the molecule is different, or that the labelling changes what a compounding pharmacy may do with a prescription. Those are two separate channels running in parallel in the same country, and a page that collapses them into a single legal story gets both wrong.

What it also does not mean is that the testing is equivalent. The certificate for lot 38-01260229 reports 99.79% purity by HPLC with ultraviolet and mass spectrometric detection across four detected peaks, and 11.31 mg of material against a 10 mg label. It carries no endotoxin test and no sterility test. FDA's stated concern for the peptides it did place in Category 2 is the risk for immunogenicity from aggregation and peptide-related impurities, which is precisely the territory those two missing assays cover. Our scoring method weights that gap heavily for that reason.

Set the three US-relevant options side by side and the shape becomes obvious. An imported vial saves money and costs recourse. A domestic vial costs a little more and returns the recourse. A compounded prescription costs meaningfully more, takes weeks, and returns something neither vial offers, which is an assessment and a label.

The evidence question sits across all three columns equally. The approved indications were paediatric growth hormone deficiency and pituitary diagnostics. PubMed holds 332 papers mentioning sermorelin, three with it in the title, and none pairing it with anti-aging, and ClinicalTrials.gov registers no studies naming it. Buying domestically does not change what is known; it changes who you can reach if the parcel is wrong.

One limit on this comparison is worth stating outright. We have verified the regulatory record, the identity data and the figures on one certificate, and we have verified the prices on the listing we link. We have not audited a compounding pharmacy, timed a real fill, or tested a vial ourselves, and we do not know how any individual parcel was handled between dispatch and your door. Where the table is empty, it is empty because we would rather show the gap than fill it with a number that reads well.

If the third column is the one you want, our guide to how to get a sermorelin prescription sets out what a prescriber asks for and what a compounding pharmacy will and will not fill. Most US buyers arriving at a for sale page do not know that column is open to them, which is the single most useful thing this page has to say.